`
`(Reference Data of Financial Statements Fiscal 2016)
`
`May 10, 2017
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
` Corporate Communications
` Tel:
` +81-(0)3-5977-5002
` Fax:
` +81-(0)3-5977-5131
` Email:
` koho@kaken.co.jp
`
`Page 1 of 5
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1590
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`
`
`1. Summary of Consolidated Financial Statements for Fiscal 2016
`
`( Figures less than one million yen have been omitted)
`
`FY
`2014
`
`FY
`2015
`
`FY
`2016
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Plan
`FY2017
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Net sales
`
`93,889
`
`109,730
`
`101,479
`
`(8,250)
`
`92.5% 101,700
`
`221
`
`100.2%
`
`Operating income
`
`20,631
`
`35,146
`
`30,707
`
`(4,439)
`
`87.4%
`
`26,800
`
`(3,907)
`
`87.3%
`
` Ratio of net sales
`
`22.0%
`
`32.0%
`
`30.3%
`
`26.4%
`
`Ordinary income
`
`20,394
`
`35,365
`
`30,981
`
`(4,384)
`
`87.6%
`
`27,000
`
`(3,981)
`
`87.1%
`
` Ratio of net sales
`
`21.7%
`
`32.2%
`
`30.5%
`
`26.5%
`
`Net income
`
`12,122
`
`21,143
`
`22,017
`
`
`
`873
`
`104.1%
`
`19,100
`
`(2,917)
`
`86.8%
`
` Ratio of net sales
`
`12.9%
`
`19.3%
`
`21.7%
`
`Per share profit(Yen)
`
`290.90
`
`510.54
`
`536.70
`
`18.8%
`
`467.32
`
`22.9%
`
`ROE
`
`16.7%
`
`25.3%
`
`Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.
` Per share profit has been calculated as if this consolidation of shares was conducted at the bigining of fiscal year 2014.
`
`Comprehensive income
`
`16,607
`
`18,444
`
`22,587
`
`4,142
`
`122.5%
`
`Capital investment
`
`2,806
`
`2,923
`
`1,415
`
`(1,507)
`
`48.4%
`
`1,700
`
`285
`
`120.1%
`
`R&D expenses
`
`7,615
`
`5,883
`
`6,450
`
`566
`
`109.6% 10,900
`
`4,450
`
`169.0%
`
`Depreciation and amortization
`
`2,400
`
`2,242
`
`1,937
`
`(305)
`
`86.4%
`
`2,100
`
`163
`
`108.4%
`
`Employee number
`
`1,503
`
`1,451
`
`1,405
`
`(46)
`
`2. Breakdown of Consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY
`2014
`
`FY
`2015
`
`FY
`2016
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`91,458
`
`107,391
`
`99,093
`
`(8,298)
`
`92.3%
`
`Pharmaceuticals,
`medical devices &
`agrochemicals
`
`Real estate
`
`2,431
`
`2,338
`
`2,386
`
`47
`
`102.0%
`
`Total
`
`93,889
`
`109,730
`
`101,479
`
`(8,250)
`
`92.5%
`
`1
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 2 of 5
`
`
`
`3. Summary of Consolidated Balance Sheets
`
`As of
` March 31,
`2015
`
`Ratio
`
`As of
` March 31,
`2016
`
`( Figures less than one million yen have been omitted)
`Y o Y
`increase
`(decrease)
`
`Ratio
`
`As of
` March 31,
`2017
`
`Ratio
`
`Assets
`
`115,135
`
`100.0% 132,991
`
`100.0% 135,060
`
`100.0%
`
` Current assets
`
`69,016
`
`59.9%
`
`88,991
`
`66.9%
`
`90,494
`
` Noncurrent assets
`
`46,118
`
`40.1%
`
`43,999
`
`33.1%
`
`44,565
`
`67.0%
`
`33.0%
`
`2,068
`
`1,502
`
`565
`
`Liabilities
`
`38,035
`
`33.0%
`
`43,116
`
`32.4%
`
`32,405
`
`24.0% (10,711)
`
` Current liabilities
`
`30,369
`
`26.4%
`
`33,861
`
`25.5%
`
`24,020
`
`17.8%
`
`(9,840)
`
` Noncurrent liabilities
`
`7,665
`
`6.7%
`
`9,255
`
`7.0%
`
`8,384
`
`6.2%
`
`(870)
`
`Net assets
`
`77,100
`
`67.0%
`
`89,875
`
`67.6% 102,655
`
`76.0%
`
`12,779
`
`23,853
`
`20.7%
`
`23,853
`
`17.9%
`
`23,853
`
`17.7%
`
`-
`
` Capital stock
`
` Capital surplus
`
`11,406
`
`9.9%
`
`11,407
`
`8.6%
`
`11,407
`
`8.4%
`
`-
`
` Retained earnings
`
`52,932
`
`46.0%
`
`68,609
`
`51.6%
`
`84,331
`
`62.4%
`
`15,722
`
` Treasury stock
` Valuation difference
` on available-for-sale securities
`
` Remeasurements of defined
` benefit plans
`
`(16,098)
`
`(14.0%)
`
`(16,301)
`
`(12.3%)
`
`(19,813)
`
`(14.7%)
`
`(3,512)
`
`5,478
`
`4.8%
`
`4,423
`
`3.3%
`
`4,611
`
`3.4%
`
`(472)
`
`(0.4%)
`
`(2,117)
`
`(1.6%)
`
`(1,734)
`
`(1.3%)
`
`187
`
`382
`
`4. Summary of Consolidated Statements of Cash Flows
`
`( Figures less than one million yen have been omitted)
`Y o Y
`increase
`(decrease)
`
`FY
`2016
`
`FY
`2014
`
`FY
`2015
`
`Net cash provided by (used in) operating activities
`
`14,737
`
`27,067
`
`15,327
`
`(11,739)
`
`Net cash provided by (used in) investing activities
`
`473
`
`(4,105)
`
`(3,503)
`
`602
`
`Net cash provided by (used in) financing activities
`
`(7,900)
`
`(5,984)
`
`(9,800)
`
`(3,816)
`
`Cash and cash equivalents at end of period
`
`24,767
`
`41,744
`
`43,767
`
`2,023
`
`2
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 3 of 5
`
`
`
`5. Summary of Non-consolidated Financial Statements for Fiscal 2016
`
`( Figures less than one million yen have been omitted)
`
`FY
`2014
`
`FY
`2015
`
`FY
`2016
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Plan
`FY2017
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Net sales
`
`91,951
`
`107,627
`
`99,949
`
`(7,677)
`
`92.9% 100,000
`
`51
`
`100.1%
`
`Operating income
`
`19,994
`
`34,468
`
`30,588
`
`(3,879)
`
`88.7% 26,700
`
`(3,888)
`
`87.3%
`
` Ratio of net sales
`
`21.7%
`
`32.0%
`
`30.6%
`
`26.7%
`
`Ordinary income
`
`19,845
`
`34,743
`
`30,863
`
`(3,880)
`
`88.8% 26,900
`
`(3,963)
`
`87.2%
`
` Ratio of net sales
`
`21.6%
`
`32.3%
`
`30.9%
`
`26.9%
`
`Net income
`
`11,777
`
`18,757
`
`21,940
`
`3,183
`
`117.0% 19,000
`
`(2,940)
`
`86.6%
`
` Ratio of net sales
`
`12.8%
`
`17.4%
`
`22.0%
`
`Per share profit(Yen)
`
`262.61
`
`452.92
`
`534.84
`
`19.0%
`
`464.87
`
`Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.
` Per share profit has been calculated as if this consolidation of shares was conducted at the bigining of fiscal year 2014.
`
`Capital investment
`
`2,777
`
`2,897
`
`1,415
`
`(1,482)
`
`48.9%
`
`1,700
`
`285
`
`120.1%
`
`R&D expenses
`
`7,615
`
`5,883
`
`6,450
`
`566
`
`109.6% 10,900
`
`4,450
`
`169.0%
`
`Depreciation and amortization
`
`2,319
`
`2,160
`
`1,937
`
`(223)
`
`89.7%
`
`2,100
`
`163
`
`108.4%
`
`Export volume
`
` Pharmaceuticals
`
` Agrochemicals
`
`7,220
`
`4,813
`
`2,407
`
`10,137
`
`7,859
`
`2,277
`
`7,223
`
`5,186
`
`2,036
`
`(2,913)
`
`(2,672)
`
`(241)
`
`71.3%
`
`66.0%
`
`89.4%
`
`Employee number
`
`1,493
`
`1,444
`
`1,398
`
`(46)
`
`6. Breakdown of Non-consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY
`2014
`
`FY
`2015
`
`FY
`2016
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Plan
`FY2017
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`84,444
`
`100,062
`
`91,934
`
`(8,128)
`
`91.9% 92,200
`
`266
`
`100.3%
`
`Pharmaceuticals &
`medical devices
`
`Agrochemicals
`
`Renting real estate
`
`5,472
`
`2,034
`
`5,620
`
`1,944
`
`5,629
`
`2,386
`
`8
`
`100.2%
`
`442
`
`122.7%
`
`5,410
`
`2,390
`
`Total
`
`91,951
`
`107,627
`
`99,949
`
`(7,677)
`
`92.9% 100,000
`
`(219)
`
`96.1%
`
`4
`
`51
`
`100.2%
`
`100.1%
`
`Note: The Company absorbed and merged with KAKEN REALTY & SERVICE CO., LTD. as of March 31, 2016. Non-consolidated
` financial results for fiscal 2016 include a portion of sales previously recorded at KAKEN REALTY & SERVICE CO., LTD.,
` such as net sales to external customers.
`
`3
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 4 of 5
`
`
`
`7. Breakdown of Sales by Main Pharmaceuticals and Medical Devices
`
`( Figures less than one hundred million yen have been omitted)
`
`FY
`2015
`
`FY
`2016
`
`%
`
`Plan
`FY2017
`
`%
`
`30,760
`
`28,978
`
`94.2% 29,700
`
`102.5%
`
`19,868
`
`21,624
`
`108.8% 23,000
`
`106.4%
`
`11,262
`
`11,036
`
`98.0%
`
`11,200
`
`101.5%
`
`4,526
`
`4,430
`
`97.9%
`
`4,600
`
`103.8%
`
`3,617
`
`3,700
`
`102.3%
`
`3,800
`
`102.7%
`
`Anti-osteoarthritis
`
`Artz
`
`Anti-nail fungus
`
`Clenafin
`
`Post-operative anti-adhesive
`
`Seprafilm
`
`Anti-hyperlipidemia
`
`Lipidil
`
`Wound healing agent
`
`Fiblast Spray
`
`Generic products
`
`13,292
`
`11,903
`
`89.6%
`
`12,000
`
`100.8%
`
`Sales of Jublia*
`
`5,722
`
`2,469
`
`43.1%
`
`-
`
`-
`
`(*including sales of API and finished product, royalty revenue and milestone revenue)
`
`8. Development Status
`
`Code
`
`Indication
`
`Stage
`
`Remarks
`
`KAG-308
`
`Ulcerative colitis
`
`PII
`
`BBI-4000
`
`KMW-1
`
`Primary focal
`hyperhidrosis
`
`PII
`
`Removal of eschar
`with thermal burns
`
`Preparing for
`clinical trial
`
`Developed jointly with Asahi Glass Co.,
`Ltd.;
`Oral-use prostaglandin analog
`
`Licensed from Brickell Biotech, Inc.;
`Topical anticholinergic
`
`Licensed from MediWound Ltd.;
`Topically-applied enzymatic product
`Overseas product name : NexoBrid
`
`4
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 5 of 5
`
`